The ideal targets of BsAbs for treating MM include B cell maturation antigen (BCMA), G protein-coupled receptor 5D (GPRC5D), CD38, and Fc receptor-like 5 (FCRL5). This evidence concerns the gene GPRC5D and Miyoshi myopathy.